Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia

Until recently, treatment advances in acute myeloid leukemia (AML) had been slow since the 1970s. However, in the past few years, as the understanding of the pathophysiology of AML has advanced, numerous treatments have been approved by the U.S. Food & Drug Administration. This article reviews t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nix, Nancy M., Price, Allyson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521119/
https://www.ncbi.nlm.nih.gov/pubmed/33537166
http://dx.doi.org/10.6004/jadpro.2019.10.8.13
Descripción
Sumario:Until recently, treatment advances in acute myeloid leukemia (AML) had been slow since the 1970s. However, in the past few years, as the understanding of the pathophysiology of AML has advanced, numerous treatments have been approved by the U.S. Food & Drug Administration. This article reviews the mechanisms of action, indications, and clinical trial details for eight novel agents, as well as the current discussions surrounding monitoring minimal residual disease.

Ejemplares similares